USANA Health Sciences (USNA) Tops Q3 EPS by 12c; Raises Outlook

USANA Health Sciences (NYSE: USNA) reported Q3 EPS of $1.24, $0.12 better than the analyst estimate of $1.12. Revenue for the quarter came in at $296.8 million versus the consensus estimate of $291.73 million.

GUIDANCE:

USANA Health Sciences sees Q4 2018 EPS of $5.00-$5.15, versus prior of $4.75-$5.05 and the consensus of $5.02. USANA Health Sciences sees Q4 2018 revenue of $1.185-1.2 billion, versus prior of $1.17-$1.2 billion the consensus of $1.19 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance